Impact of high-throughput screening in biomedical research
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
High-throughput screening (HTS) has been postulated in several quarters to be a contributory factor to the decline in productivity in the pharmaceutical industry. Moreover, it has been blamed for stifling the creativity that drug discovery demands. In this article, we aim to dispel these myths and present the case for the use of HTS as part of a proven scientific tool kit, the wider use of which is essential for the discovery of new chemotypes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell-based phenotypic screening of chemical libraries represents a powerful tool to identify new potential drugs48.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [48]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“HTS laboratories have pioneered and implemented rigorous quality assurance methods, such as Z′ trend monitoring”
MethodCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“These efforts typically take 2–3 years in most drug discovery companie”
BackgroundDrug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237 · cited 1×
“There have been numerous analyses of pharmaceutical industry productivity, and several of these have blamed high-throughput screening (HTS) as a factor undermining the creativity that has sustained the industry over the past centur”
BackgroundDiscovery and development of sorafenib: a multikinase inhibitor for treating cancer
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2130 · Cited by 1,829
Lessons from 60 years of pharmaceutical innovation
Munos, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2961 · Cited by 1,207
Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4721-4732.2005 · Cited by 1,152
Hit and lead generation: beyond high-throughput screening
Bleicher, K. H., Böhm, H.-J., Müller, K., & Alanine, A. I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1086 · Cited by 1,056
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Gao, M., Nettles, R. E., Belema, M., Snyder, L. B., Nguyen, V. N., Fridell, R. A., Serrano-Wu, M. H., Langley, D. R., Sun, J.-H., O’Boyle II, D. R., et al. (2010) · Nature · doi:10.1038/nature08960 · Cited by 939 · cited 1×
“This approach was used to discover compounds that inhibited hepatitis C virus replication and, after consequent optimization, the approach yielded efficacious clinical candidates with a broad genotype coverag”
MethodA Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Research works printed but not linked: 5
- Landers, P. Human Element: drug industry's big push into technology falls short — testing machines were built to streamline research — but may be stifling it — officials see payoff after 2010. The Wall Street Journal 1 (24 Feb 2004).
- Mullin, R. As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82, 23–32 (2004).
- HTStec Limited. Cellular Assay Reagents Trends 2009 Report (Cambridge, UK, 2009).
- LaMattina, J. L. (ed.) in Drug Truths: Dispelling the Myths About Pharma R&D 65–66 (John Wiley and Sons, Inc., Hoboken, New Jersey, 2009).
- Inglese, J. in Ask the Expert Forum, ACS Chemical Biology. ACS Publications [online] http://community.acs.org/ChemBiol/AsktheExpert/AsktheExpertArchive/tabid/67/Default.aspx (2008).
Cited by
Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
“To overcome the inherent limitations of many individual small-molecule collections (Macarron et al., 2011), we assembled a custom screening library of 9,517 small molecules derived from a starting pool of 3,372,615 commercially available compounds that were filtered in silico on the basis of drug…”
MethodNatural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Natural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
“, (also from GSK) when looking at different disease targets [247].”
BackgroundThe re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Antibacterial drug discovery in the resistance era
Brown, E. D., & Wright, G. D. (2016) · Nature · doi:10.1038/nature17042 · Cited by 2,247
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Open Graph Benchmark: Datasets for Machine Learning on Graphs
Hu, W., Fey, M., Žitnik, M., Dong, Y., Ren, H., Liu, B., Catasta, M., & Leskovec, J. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.00687 · Cited by 470
“…protein associations that are measured experimentally by a high-throughput technology ( e.g. , cost-effective, automated experiments that make large scale repetition feasible (Macarron et al., 2011; Bajorath, 2002; Younger et al., 2017)) or are obtained computationally ( e.g. , via text-mining).”
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Target identification and mechanism of action in chemical biology and drug discovery
Schenone, M., Dančík, V., Wagner, B. K., & Clemons, P. A. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1199 · Cited by 1,096
Twenty years on: the impact of fragments on drug discovery
Erlanson, D. A., Fesik, S. W., Hubbard, R. E., Jahnke, W., & Jhoti, H. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.109 · Cited by 1,000
Role of computer-aided drug design in modern drug discovery
Macalino, S. J. Y., Gosu, V., Hong, S., & Choi, S. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0640-5 · Cited by 762
“…to be a big part of the drug discovery process in the pharmaceutical industry due to its high success rate, lack of primary understanding of the molecular mechanism behind the activity of the identified hits can hamper the search of promising candidates (Macarron et al. 2011; Lionta et al. 2014).”
BackgroundDeep learning for molecular design—a review of the state of the art
Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00039a · Cited by 683
The pharmaceutical industry and natural products: historical status and new trends
David, B., Wolfender, J.-L., & Dias, D. A. (2015) · Phytochemistry Reviews · doi:10.1007/s11101-014-9367-z · Cited by 579
“theory, can lead to the identification of NCEs and hits, but the serendipity behind analyzing a less uncommon terrestrial or marine organism should not be overlooked (Michael et al. 2008; Frearson and Collie 2009; Macarrón et al. 2011).”
BackgroundMethodDiscovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
“Lastly, the ideal size and composition of a compound screening file is still a matter of discussion that goes beyond the scope of this review (Akella and DeCaprio, 2010; Macarron et al., 2011).”
BackgroundInfluentialBig-data approaches lead to an increased understanding of the ecology of animal movement
Nathan, R., Monk, C. T., Arlinghaus, R., Adam, T., Alós, J., Assaf, M., Baktoft, H., Beardsworth, C. E., Bertram, M. G., Bijleveld, A. I., et al. (2022) · Science · doi:10.1126/science.abg1780 · Cited by 545
“To assess which wildlife tracking techniques can generate big data for movement ecology research, we adjusted four major criteria used to define high-throughput data collection systems in other scientific fields (7, 15).”
MethodKamerzell, T. J., Esfandiary, R., Joshi, S. B., Middaugh, C. R., & Volkin, D. B. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.07.006 · Cited by 510
WILDS: A Benchmark of in-the-Wild Distribution Shifts
Koh, P. W., Sagawa, S., Marklund, H., Xie, S. M., Zhang, M., Balsubramani, A., Hu, W., Yasunaga, M., Phillips, R. L., Gao, I., et al. (2020) · arXiv · doi:10.48550/arxiv.2012.07421 · Cited by 518
The discovery of first-in-class drugs: origins and evolution
Eder, J., Sedrani, R., & Wiesmann, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4336 · Cited by 514
Machine learning approaches to drug response prediction: challenges and recent progress
Adam, G., Rampášek, L., Safikhani, Z., Smirnov, P., Haibe-Kains, B., & Goldenberg, A. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0122-1 · Cited by 425
“Since then, high-throughput in vitro drug screens of cancer cell lines (CCLs) derived by immortalization of human cancer cells became popular experimental bases for discovery of multi-omic underpinnings of drug sensitivity and resistance 16 .”
BackgroundTao, Y., Zhang, Y., Cheng, Y., & Wang, Y. (2013) · Biomedical Chromatography · doi:10.1002/bmc.2761 · Cited by 453
Big data and artificial intelligence modeling for drug discovery
Zhu, H. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023324 · Cited by 455
“Facilitated by the combined efforts of HTS and combinatorial chemical synthesis, modern screening programs produce enormous amounts of biological data, especially regarding drug responses on specific targets (29, 30).”
BackgroundDiversity-oriented synthesis: producing chemical tools for dissecting biology
O' Connor, C. J., Beckmann, H. S. G., & Spring, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35023h · Cited by 434
Next-Generation Experimentation with Self-Driving Laboratories
Häse, F., Roch, L. M., & Aspuru-Guzik, A. (2019) · Trends in Chemistry · doi:10.1016/j.trechm.2019.02.007 · Cited by 426
Finding the sweet spot: the role of nature and nurture in medicinal chemistry
Hann, M. M., & Keserü, G. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3701 · Cited by 411
Bender, A., & Cortés-Ciriano, I. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.009 · Cited by 405
Identification and characterization of Cardiac Glycosides as senolytic compounds
Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12888-x · Cited by 384
Recent Advances in Droplet Microfluidics
Ding, Y., Howes, P. D., & deMello, A. J. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.9b05047 · Cited by 357
Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis
Niazi, S. K., & Mariam, Z. (2023) · Pharmaceuticals · doi:10.3390/ph17010022 · Cited by 336
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Zhao, S., & Iyengar, R. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134520 · Cited by 358
“The potential of false positives may be decreased through the application of orthogonal experimental techniques such as high-content screening (74), in vitro ADMET (75), medicinal chemistry techniques (76, 77), binding screens (78), and gene regulation (79).”
BackgroundTherapies for rare diseases: therapeutic modalities, progress and challenges ahead
Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357
DNA-Encoded Chemical Libraries: A Comprehensive Review with Succesful Stories and Future Challenges
Gironda-Martínez, A., Donckele, E. J., Samain, F., & Neri, D. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00118 · Cited by 344
The strategies and techniques of drug discovery from natural products
Zhang, L., Song, J., Kong, L., Yuan, T., Li, W., Zhang, W., Hou, B., Lu, Y., & Du, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107686 · Cited by 313
Antimalarial drug discovery — approaches and progress towards new medicines
Flannery, E. L., Chatterjee, A. K., & Winzeler, E. A. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3138 · Cited by 313
RNA Display Methods for the Discovery of Bioactive Macrocycles
Huang, Y., Wiedmann, M. M., & Suga, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00430 · Cited by 298
Structure-based drug screening for G-protein-coupled receptors
Shoichet, B. K., & Kobilka, B. K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.007 · Cited by 294
“Gribbon P, Sewing A. High-throughput drug discovery: what can we expect from HTS?”
BackgroundInfluentialA Structure-Based Platform for Predicting Chemical Reactivity
Sandfort, F., Strieth-Kalthoff, F., Kühnemund, M., Beecks, C., & Glorius, F. (2020) · Chem · doi:10.1016/j.chempr.2020.02.017 · Cited by 288
A Guide to In Silico Drug Design
Chang, Y., Hawkins, B. A., Du, J. J., Groundwater, P. W., Hibbs, D. E., & Lai, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010049 · Cited by 250
“There are various strategies that can be used in this screening, involving physical methods, such as mass spectrometry [13], fragment screening [14,15], nuclear magnetic resonance (NMR) screening [16], DNA encoded chemical libraries [17], high throughput screening (HTS) (such as protein or cells) [18] or in silico met…”
BackgroundAware, C. B., Patil, D. N., Suryawanshi, S. S., Mali, P. R., Rane, M. R., Gurav, R. G., & Jadhav, J. P. (2022) · South African Journal of Botany · doi:10.1016/j.sajb.2022.05.028 · Cited by 238
Chemical Space of DNA-Encoded Libraries: Miniperspective
Franzini, R. M., & Randolph, C. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01874 · Cited by 271
DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
Wang, J., Liu, X., Shen, S., Deng, L., & Liu, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab390 · Cited by 261
Discovering Cell-Adhesion Peptides in Tissue Engineering: Beyond RGD
Huettner, N., Dargaville, T. R., & Forget, A. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.01.008 · Cited by 263
Targeting Glycosylation: A New Road for Cancer Drug Discovery
Costa, A. F., Campos, D., Reis, C. A., & Gomes, C. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.04.002 · Cited by 263
Nanoplasmonic sensors for biointerfacial science
Jackman, J. A., Rahim Ferhan, A., & Cho, N.-J. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00494f · Cited by 258
Leng, Y., Sun, K., Chen, X., & Li, W. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00382a · Cited by 258
In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery
de Souza Neto, L. R., Moreira-Filho, J. T., Neves, B. J., Maidana, R. L. B. R., Guimarães, A. C. R., Furnham, N., Andrade, C. H., & Silva, F. P. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00093 · Cited by 240
“…the more efficient chemical space sampling (Coutard et al., 2014; Mondal et al., 2015) and the relative low cost to implement the FBDD, as it can be seen from comparing the usual size of the HTS library (thousands of compounds) with fragment libraries (hundreds of compounds) (Macarron et al., 2011).”
BackgroundA proteome-wide atlas of lysine-reactive chemistry
Abbasov, M. E., Kavanagh, M. E., Ichu, T.-A., Lazear, M. R., Tao, Y., Crowley, V. M., am Ende, C. W., Hacker, S. M., Ho, J., Dix, M. M., et al. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00765-4 · Cited by 236
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00758-2 · Cited by 187
“In the discovery of new chemical entities, classical drug discovery relies heavily on HTS techniques to test large libraries of chemical compounds against the identified target [15, 25].”
Unraveling Plant Natural Chemical Diversity for Drug Discovery Purposes
Lautié, E., Russo, O., Ducrot, P., & Boutin, J. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00397 · Cited by 233
“For example, in midsize pharmaceutical companies, it is common to find libraries from 30,000 up to 500,000 compounds, while for big pharmas, the numbers are more in the 500,000 to several million ranges (Macarron et al., 2011) .”
BackgroundValencia, P. M., Pridgen, E. M., Rhee, M., Langer, R., Farokhzad, O. C., & Karnik, R. (2013) · ACS Nano · doi:10.1021/nn403370e · Cited by 235
Fluorescence polarization assays in high-throughput screening and drug discovery: a review
Hall, M. D., Yasgar, A., Peryea, T., Braisted, J. C., Jadhav, A., Simeonov, A., & Coussens, N. P. (2016) · Methods and Applications in Fluorescence · doi:10.1088/2050-6120/4/2/022001 · Cited by 225
The Role of Omics in the Application of Adverse Outcome Pathways for Chemical Risk Assessment
Brockmeier, E. K., Hodges, G., Hutchinson, T. H., Butler, E., Hecker, M., Tollefsen, K. E., Garcia-Reyero, N., Kille, P., Becker, D., Chipman, K., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx097 · Cited by 232
Čerpnjak, K., Zvonar, A., Gašperlin, M., & Vrečer, F. (2013) · Acta Pharmaceutica · doi:10.2478/acph-2013-0040 · Cited by 224
Adversarial Threshold Neural Computer for Molecular de Novo Design
Putin, E., Asadulaev, A., Vanhaelen, Q., Ivanenkov, Y., Aladinskaya, A. V., Aliper, A., & Zhavoronkov, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01137 · Cited by 211
Machine learning classification can reduce false positives in structure-based virtual screening
Adeshina, Y. O., Deeds, E. J., & Karanicolas, J. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000585117 · Cited by 223
“This expansion of chemical space in which to search, along with the high cost of setting up and implementing an HTS screen, has increasingly driven the use of complementary computational approaches.”
DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Ye, C., Ho, D. J., Neri, M., Yang, C., Kulkarni, T., Randhawa, R., Henault, M., Mostacci, N., Farmer, P., Renner, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06500-x · Cited by 222
High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases
Aldewachi, H., Al-Zidan, R. N., Conner, M. T., & Salman, M. M. (2021) · Bioengineering · doi:10.3390/bioengineering8020030 · Cited by 207
“HTS aims to decrease the costs of drug invention [59,60].”
Engineering a Brain Cancer Chip for High-throughput Drug Screening
Fan, Y., Nguyen, D. T., Akay, Y., Xu, F., & Akay, M. (2016) · Scientific Reports · doi:10.1038/srep25062 · Cited by 216
Häse, F., Aldeghi, M., Hickman, R. J., Roch, L. M., & Aspuru-Guzik, A. (2021) · Applied Physics Reviews · doi:10.1063/5.0048164 · Cited by 170
“[6] Florian Häse, Ignacio Fdez Galván, Alán Aspuru-Guzik, Roland Lindh, and Morgane Vacher.”
BackgroundMicrofluidics for Drug Development: From Synthesis to Evaluation
Liu, Y., Sun, L., Zhang, H., Shang, L., & Zhao, Y. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01289 · Cited by 202
Artificial intelligence foundation for therapeutic science
Huang, K., Fu, T., Gao, W., Zhao, Y., Roohani, Y., Leskovec, J., Coley, C. W., Xiao, C., Sun, J., & Zitnik, M. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01131-2 · Cited by 207
Sprouts and Microgreens: Trends, Opportunities, and Horizons for Novel Research
Galieni, A., Falcinelli, B., Stagnari, F., Datti, A., & Benincasa, P. (2020) · Agronomy · doi:10.3390/agronomy10091424 · Cited by 190
Rigorous Free Energy Simulations in Virtual Screening
Cournia, Z., Allen, B. K., Beuming, T., Pearlman, D. A., Radak, B. K., & Sherman, W. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00116 · Cited by 194
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
Lee, J. A., Uhlik, M. T., Moxham, C. M., Tomandl, D., & Sall, D. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201649s · Cited by 192
Wawer, M. J., Li, K., Gustafsdottir, S. M., Ljosa, V., Bodycombe, N. E., Marton, M. A., Sokolnicki, K. L., Bray, M.-A., Kemp, M. M., Winchester, E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410933111 · Cited by 196
“Biochemical and cell-based high-throughput screening (HTS) is routinely used to discover novel bioactive molecules through unbiased testing of up to several million compounds per screen (6).”
BackgroundModeling the expansion of virtual screening libraries
Lyu, J., Irwin, J. J., & Shoichet, B. K. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01234-w · Cited by 193
Delocalized, asynchronous, closed-loop discovery of organic laser emitters
Strieth-Kalthoff, F., Hao, H., Rathore, V., Derasp, J., Gaudin, T., Angello, N. H., Seifrid, M., Trushina, E., Guy, M., Liu, J., et al. (2024) · Science · doi:10.1126/science.adk9227 · Cited by 160
“…intelligence (AI) tools for materials science ( 6 , 7 ) along with major advances in automation and high-throughput experimentation (HTE) ( 8 , 9 ) and, eventually, the integration of both automated experimentation and automated decision-making into self-driving laboratories (SDLs) ( 10 –…”
BackgroundSecond-generation DNA-templated macrocycle libraries for the discovery of bioactive small molecules
Usanov, D. L., Chan, A. I., Maianti, J. P., & Liu, D. R. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0033-8 · Cited by 183
“(2) In addition to increasing the number of scaffold codons (from 8 to 32 or 80), we developed an efficient DNA-compatible on-bead Boc-deprotection method and validated a number of new building blocks that together substantially expand scaffold and building block diversity of DNA-templated macrocycles.”
MethodWhere Do Recent Small Molecule Clinical Development Candidates Come From?
Brown, D. G., & Boström, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00675 · Cited by 176
Thornburg, C. C., Britt, J. R., Evans, J. R., Akee, R. K., Whitt, J. A., Trinh, S. K., Harris, M. J., Thompson, J. R., Ewing, T. L., Shipley, S. M., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00389 · Cited by 171
Meli, R., Morris, G. M., & Biggin, P. C. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.885983 · Cited by 197
“The discovery pipeline for small-molecule drugs usually starts with the identi fi cation of a protein target against which a hit compound is identi fi ed by high throughput screening (HTS) (Mayr and Bojanic 2009; Macarron et al., 2011).”
BackgroundSurface acoustic waves for on-demand production of picoliter droplets and particle encapsulation
Collins, D. J., Alan, T., Helmerson, K., & Neild, A. (2013) · Lab on a Chip · doi:10.1039/c3lc50372k · Cited by 175
Fragment Based Drug Design: From Experimental to Computational Approaches
Kumar, A., Voet, A., & Zhang, K. Y. J. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803530467 · Cited by 168
“Nowadays, with significant successes of using high concentration screening by biological assays reported, many groups in pharmaceutical industry are using fragments in HTS screening at higher concentration to develop target focused sets of fragments for further biophysical screening [15] .”
BackgroundInfluentialMolecular complexity and fragment-based drug discovery: ten years on
Leach, A. R., & Hann, M. M. (2011) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2011.05.008 · Cited by 169
Creating and screening natural product libraries
Wilson, B. A. P., Thornburg, C. C., Henrich, C. J., Grkovic, T., & O’Keefe, B. R. (2020) · Natural Product Reports · doi:10.1039/c9np00068b · Cited by 177
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Deep learning approaches for de novo drug design: An overview
Wang, M., Wang, Z., Sun, H., Wang, J., Shen, C., Weng, G., Chai, X., Li, H., Cao, D., & Hou, T. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.10.001 · Cited by 184
Screening Technologies for Small Molecule Discovery: The State of the Art
Janzen, W. P. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.015 · Cited by 176
Self-citationPharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-alawi, W., Safikhani, Z., & Haibe-Kains, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx911 · Cited by 155
Zhu, H., Zhang, J., Kim, M. T., Boison, A., Sedykh, A., & Moran, K. (2014) · Chemical Research in Toxicology · doi:10.1021/tx500145h · Cited by 154
SyntaLinker: automatic fragment linking with deep conditional transformer neural networks
Yang, Y., Zheng, S., Su, S., Zhao, C., Xu, J., & Chen, H. (2020) · Chemical Science · doi:10.1039/d0sc03126g · Cited by 172
Allosteric sites: remote control in regulation of protein activity
Guarnera, E., & Berezovsky, I. N. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.10.004 · Cited by 162
Buterez, D., Janet, J. P., Kiddle, S. J., Oglić, D., & Lió, P. (2024) · Nature Communications · doi:10.1038/s41467-024-45566-8 · Cited by 174
Niazi, S. K. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s424991 · Cited by 184
Harnessing Allostery: A Novel Approach to Drug Discovery
Lu, S., Li, S., & Zhang, J. (2014) · Medicinal Research Reviews · doi:10.1002/med.21317 · Cited by 148
Brighty, G. J., Botham, R. C., Li, S., Nelson, L. T., Mortenson, D. E., Li, G., Morisseau, C. H. P., Wang, H., Hammock, B. D., Sharpless, K. B., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0530-4 · Cited by 148
The Essential Roles of Chemistry in High-Throughput Screening Triage
Dahlin, J. L., & Walters, M. A. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.60 · Cited by 161
Magnetic sensing platform technologies for biomedical applications
Lin, G., Makarov, D., & Schmidt, O. G. (2017) · Lab on a Chip · doi:10.1039/c7lc00026j · Cited by 144
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106774 · Cited by 144
AI is a viable alternative to high throughput screening: a 318-target study
Program, T. A. A., Wallach, I., Bernard, D., Nguyen, K. T., Ho, G., Morrison, A., Stecuła, A., Rosnik, A. M., O’Sullivan, A. M., Davtyan, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-54655-z · Cited by 149
Microfluidic static droplet arrays with tuneable gradients in material composition
Sun, M. Z., Bithi, S. S., & Vanapalli, S. A. (2011) · Lab on a Chip · doi:10.1039/c1lc20709a · Cited by 141
Dark chemical matter as a promising starting point for drug lead discovery
Wassermann, A. M., Lounkine, E., Hoepfner, D., Goff, G. L., King, F. J., Studer, C., Peltier, J. M., Grippo, M. L., Prindle, V. C., Tao, J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1936 · Cited by 148
Key cell signaling pathways modulated by zerumbone: Role in the prevention and treatment of cancer
Prasannan, R., Kalesh, K., Shanmugam, M. K., Nachiyappan, A., Ramachandran, L., Nguyen, A. H., Kumar, A. P., Lakshmanan, M., Ahn, K. S., & Sethi, G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.07.015 · Cited by 145
“Several promising natural products and natural product-inspired compounds are currently in clinical and pre-clinical developmental stages for cancer treatment [7,11–13].”
BackgroundBeckmann, H. S. G., Nie, F., Hagerman, C. E., Johansson, H., Tan, Y. S., Wilcke, D., & Spring, D. R. (2013) · Nature Chemistry · doi:10.1038/nchem.1729 · Cited by 137
Automated screening for small organic ligands using DNA-encoded chemical libraries
Decurtins, W., Wichert, M., Franzini, R. M., Buller, F., Stravs, M. A., Zhang, Y., Neri, D., & Scheuermann, J. (2016) · Nature Protocols · doi:10.1038/nprot.2016.039 · Cited by 134
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
“For example, many GPCRs engage multiple signalling pathways and their properties are modified by interactions with other proteins, including other classes of GPCR (Enna and Williams, 2009; Heilker et al., 2009; Maccaron et al., 2011; Terstappen et al., 2007).”
BackgroundInfluentialTinworth, C. P., & Young, R. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01596 · Cited by 140
Metadata
- Authors
- Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., Green, D. V. S., Hertzberg, R. P., Janzen, W. P., Paslay, J. W., Schopfer, U., & Sittampalam, G. S.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Novartis (United States) (US)
- Abbott (United States) (US)
- Sanofi (France) (FR)
- GlaxoSmithKline (United Kingdom) (GB)
- GlaxoSmithKline (United States) (US)
- University of North Carolina at Chapel Hill (US)
- The University of Kansas Cancer Center (US)
- Novartis (Switzerland) (CH)
- Pfizer (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 188-195
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2031441006
- Cited by
- 1,364
- References
- 65
- Citations by year
- 2026: 113 · 2025: 117 · 2024: 99 · 2023: 103 · 2022: 82 · 2021: 107 · 2020: 106 · 2019: 77 · 2018: 105 · 2017: 87 · 2016: 96 · 2015: 64 · 2014: 61 · 2013: 73 · 2012: 54
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- high-throughput screening, drug discovery, chemical biology
- MeSH terms
- Animals, Drug Evaluation, Preclinical, Humans, Drug Design, Biomedical Research, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.